r/RobinHoodPennyStocks

A lot of the discussion around ARM today centers on its ~18% China revenue exposure (mostly royalty revenue through licensees like Samsung and SK Hynix). Ran the EPS sensitivity instead of just looking at the headline percentage: a 10% cut to that China revenue only moves EPS by about $0.01. The royalty/licensing model has enough operating leverage that revenue shocks don't translate 1:1 into earnings hits.

HPE was up almost identically (+10.0%) the same session, which points more toward broad tech/infra rotation than an ARM-specific catalyst. The AI infrastructure and custom silicon design-win narrative ("physical AI buildout" robotics, edge, data centers) is getting cited as the underlying driver.

Full writeup: https://metricshour.com/briefs/2026-07-10/

Curious if others are seeing the same EPS math or reading the exposure risk differently.

Following the broad response and discussion around my previous post, I thought it was worth revisiting one part of the DeepView thesis that may be especially useful for those newer to the Spectral AI community: the potential health economics. This has been discussed before, but I think it’s important when considering commercialization and adoption.

Spectral estimates ~$24,000 in potential savings per burn stay, while an earlier SEC filing estimated ~$63,100 per DFU stay. These are company estimates, not yet proven real-world savings — which is exactly why the BARDA-supported health-economic and outcome research is interesting.

I also think this needs to be viewed in the context of management’s longer-term strategy. DeepView isn’t intended to remain simply a burn device. The broader vision is a wound-diagnostics medtech platform, with burn as the first FDA-authorized indication and potential expansion into DFU and other wounds. If successful, the opportunity becomes much larger than the burn-center market alone.

The economics could also extend beyond treatment itself. Better Day-One wound assessment could improve triage — determining who needs routine care, transfer to a burn/trauma center, or earlier intervention — potentially reducing unnecessary transfers, procedures, hospital stays and complications.

Longer term, if real-world evidence confirms meaningful reductions in total cost of care across wound indications, the incentive could extend beyond hospitals. Insurers and other payers could potentially encourage or incentivize objective wound assessment to reduce downstream healthcare costs.

That’s speculative today. But BARDA is helping fund the research that could determine whether this broader economic thesis holds up in the real world.

Sources:
Current SEC filing / BARDA (March 31, 2026):
https://www.sec.gov/Archives/edgar/data/1833498/000121390026055226/ea0289162-10q_spectral.htm

Earlier SEC filing / DFU estimate (December 31, 2023):
https://www.sec.gov/Archives/edgar/data/1833498/000121390024027863/ea0202419-10k_spectral.htm

I have about $70k in risk capital that I can afford to be aggressive with, and I’m considering building a position in AUR, KEEL, or ONDS.

I’m looking for the strongest long-term upside—not just whichever stock is getting the most hype right now. Which company has the best combination of technology, market opportunity, execution, and potential to become a legitimate multibagger?

Would you put the money into one, divide it among all three, or avoid them entirely? I’d especially like to hear the bear case for each one.

If you know of any other overlooked beauties with serious upside, drop them below and explain the thesis.

Two small-cap plays with potential  heading into earnings this week. Both companies have had significant recent developments since their last 1Q financial reports, so the forward-looking management commentary may be more important than the actual EPS number.

$BESS — Bimergen Energy

Friday close: $2.88
Earnings: Friday, August 14    

Bimergen is a micro-cap U.S. energy infrastructure developer focused on utility-scale battery energy storage (BESS) and solar projects. The company's capital-light development model, developing projects and then monetizing them through strategic partners is innovative.

BESS is developing a rapidly growing project pipeline. Bimergen has been developing projects in ERCOT/Texas, where grid-balancing and long-duration storage are becoming increasingly valuable.

With a market cap of just $20.4 Million, BESS appears to be undervalued when you consider recent transactions. With the recent transactions (the last two falling in the 3Q) the Q will not show the substantial cash position increase, although most likely included in the Management's Discussion. 

Last 3 major press releases

•   July 28 — $8.9M transaction

Bimergen announced the closing of the 100 MW / 400 MWh Redbird project plus two Texas projects totaling another 80 MWh.

The transaction provided Bimergen with $6.4M in cash, with another $2.5M potentially payable based on Redbird milestones.

•   July 14 — 400 MWh Wildfire project

With Wildfire, FPUSA had closed or selected approximately 1.8 GWh of projects, representing about 90% of its 2 GWh capacity reservation with Eos Energy $EOSE.

•  June 18 — Redbird purchase order

Eos Energy Enterprises announced the first purchase order under FPUSA's 2 GWh capacity reservation agreement. The order supports Bimergen-developed Redbird, a 100 MW / 400 MWh Texas battery project using Eos Z3 technology.

$SKYX — SKYX Platforms

Friday close: $1.22
Earnings: Thursday, August 13 

SKYX is developing plug-and-play smart electrical and smart-home technologies, ie. ceiling outlets, lighting, fans and other connected building technologies.

The company has been expanding beyond residential applications into hotels, commercial buildings and international markets.

Q1 revenue was $22 Million, up a disappointing YoY, giving SKYX nine consecutive quarters of YoY growth. With the pending 2Q report, investors will see whether the revenues are accelerating. According to recent filings, institutions have been accumulating in the past two months despite SKYX being eliminated from the Russell 2000 and Russell 3000 Indexes.

 Last 3 significant press releases

•  July 22 — Marriott hotel deployment

SKYX announced that the 190-room Marriott City Center Hotel in Durham, North Carolina will be using SKYX's plug-and-play technologies during the  full hotel renovation.

It probably cannot be overstated how significant the potential is for this recurring-revenue model from installations, upgrades, AI services, monitoring and subscriptions.

•   June 10 — Mozart Prague / Accor

SKYX announced that its technologies will be deployed during the renovation of the 5-star Mozart Prague hotel, owned by Group OTT and operated by global hospitality company Accor.

•   May 20 — Eurofase licensing deal

SKYX signed a licensing agreement with Eurofase, a global lighting company, securing SKYX with another distribution channel for its patented technology across the U.S., Canada and international markets.

WIth Eurofase bearing the costs of manufacturing and distribution, SKYX can expand it distribution footprint with less capex than going it alone. The fact that Eurofase sees value in signing a licensing agreement is, in itself, a positive.

Watch for potential "surprise" earnings and/or better than expected management guidance that could expand investor awareness.

In the dog days of summer, when many traders and investors in the microcap market sector can be distracted with vacations, companies with low public floats can "go on sale".  These two companies in the healthcare sector fits this description. Check the charts on both--recently going from recent highs to recent lows. GOVX traded over $4 in the past few weeks and closed on 4/03 at $0.70. MODD was at $6.00...now at $2.23. Monitoring these two medical/healthcare plays for news can change investor sentiment in a "heartbeat".

Potential Catalysts for Geovax (Nasdaq:GOVX)

• GEO-MVA Phase 3 immuno-bridging trial initiation expected in Third/Fourth Quarter 2026
  • The company's near term catalyst would formally begin the pivotal study supporting an expedited European regulatory pathway.
  • GEO-MVA is GeoVax's most immediate commercialization opportunity.
• Announcement that first GEO-MVA patient has been dosed
  • First patient dosing press release usually follows trial initiation.
  • Typically attracts micro-cap biotech investor attention stocks.
• AGE1 manufacturing milestone
  • AGE1 continuous avian cell line platform is a proprietary vaccine manufacturing technology that GeoVax licenses for producing its Modified Vaccinia Ankara (MVA) vaccines, including GEO-MVA.
  • Significant because scalable manufacturing is integral to GEO-MVA commercialization and positioning for U.S./European biosecurity initiative

    

• Government or biodefense partnership announcements progress with Gedeptin Phase 2 
  • Continues to position GEO-MVA as a strategic biodefense asset.
  • Potential for a BARDA, European procurement, or strategic manufacturing partnership. BARDA develops medical countermeasures that address the public health and medical consequences of chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases.
  • Current management guidance points to the Phase 2 combination study beginning in 2027, however near-term news could include protocol, regulatory, or preclinical combination updates before the beginning of clinical trials.
• Business development/licensing agreements
  • Management has repeatedly emphasized a partnership-oriented strategy for both GEO-MVA and Gedeptin.
  • Any regional licensing or co-development deal would likely be viewed positively because it could reduce future financing needs.

Near term catalysts for Modular Medical (Nasdaq:MODD)

• Quarterly reports showing initial Pivot revenue expected
• Commercial rollout expansion into additional U.S. metro markets
  • Management has indicated it intends to expand commercialization initially across five (5) major metropolitan markets in 3Q and 4Q of 2026
  • Investors will watch for new distribution regions, expansion of diabetes clinic and medical practice adoption
• Insurance reimbursement / payer coverage announcements potential
  • Easier reimbursement dramatically increases patient adoption
  • Potential announcements include commercial insurer coverage, pharmacy benefit inclusion in pharmacy benefit plans and reduced patient out-of-pocket costs
• Patient adoption and repeat usage in future press releases
  • Possible news include:
    • active users
    • refill orders
    • patient retention
    • physician satisfaction
    • patient testimonials
• Strategic partnerships/Joint Ventures Announcement Potential
  • Potential announcements may include:
    • diabetes clinics
    • insulin manufacturers
    • distributors
    • pharmacy partners
    • digital health companies
• Additional intellectual property / patent announcements
  • Newly issued patents or expanded IP protection can support higher enterprise valuation
• European (CE Mark) progress
  • Management expects CE Mark clearance around Q2 2027.

Watching for news in these two stocks that can quickly shift trader and investor sentiment neutral and/or negative to positive can provide an opportunity. Additionally, corporate development news can attract potential strategic partnerships or acquisition.

Please do your own research, including investor presentations on company websites,, SEC filings and view technical stock charts.